Navigation Links
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
Date:4/7/2011

OSAKA, Japan and NORWOOD, Mass., April 7, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Boston Biomedical, Inc. ("BBI"), today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.

BBI608 is an orally administered, first-in-class, small molecule anti-cancer drug that targets highly malignant cancer stem cells as well as other heterogeneous cancer cells. In clinical trials to date, BBI608 has shown excellent safety, favorable pharmacokinetics, and encouraging signs of anticancer activity.  BBI608 is under phase I extension clinical studies in colorectal cancer and phase Ib/II trials in multiple solid tumor types.

Under the terms of the agreement, BBI will receive $15million of upfront payment and clinical trial support upon signing.  Based on the outcome of the clinical trials, DSP has the option to acquire exclusive rights for the development and commercialization for BBI608 in Japan. In addition, DSP has an exclusive negotiation right for the United States and Canada for a certain time.  During this option agreement period, DSP will pay a maximum of $55million for part of the development costs of BBI608 and for continuation of the option. Assuming DSP exercise the option for Japan, upon successful clinical development and commercialization of BBI608 in Japan, BBI could receive a maximum of approximately $100million in aggregate, including milestone payments associated with successful development and commercialization, in addition to running royalties.

Masayo Tada, President and chief executive officer of DSP, said, "DSP recognizes oncology as an area with high unmet medical needs and has already spent substantial effort, defining it as a major specialty area. We are delighted to enter into this strategic partnership with Boston Biomedical in the oncology area to d
'/>"/>

SOURCE Boston Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
3. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
4. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
5. CVS/pharmacy Debuts the "To Your Health" Program in Atlanta Bringing 60 Free Health Screening Events to the Community
6. CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste
7. Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
8. Harnessing Patients Good Intentions Can Cut 33% of Americas Pharmacy-Related Waste
9. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
10. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
11. ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo Nordisk, a ... (CGRT), today announced a multi-year extension of their partnership, that ... No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by ... Kimball, 29, from Camarillo, California ... in the history of INDYCAR to win a race at ...
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "China Chemical Pharmaceutical Industry Report, ... http://photos.prnewswire.com/prnh/20130307/600769 ... preparation and active pharmaceutical ingredient (API), and the ... generally higher than that of the API over ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... 18 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... is developing a potential cancer drug,that seeks to ... a pre-clinical product being developed by Aida,s Shanghai,Qiaer ... the,function of extracted fragments of Vasostatin, an inhibitor ...
... CARLSBAD, Calif., April 18 Isis,Pharmaceuticals, Inc. ... of two studies,designed to assess the impact ... Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB),Conference ... in a poster,entitled "Antisense Inhibition of Apolipoprotein ...
Cached Medicine Technology:Aida Announces New Anti-Cancer Drug Under Development 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 3Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 4
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 2014 Emergo Group, Inc., a medical ... in North and South America, Europe, the Middle East, ... participants for its 2015 Medical Device Industry Survey. Each ... upcoming business and market trends as well as regulatory ... targets areas including:, , Overall prospects ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... large proportion of Medicare expenditures for nursing home residents ... aggressive treatments that may be avoidable and of limited ... Institute for Aging Research, an affiliate of Harvard Medical ... Archives of Internal Medicine on Jan. 10, 2011. ...
... January 10, 2011 -- Previous research regarding the association ... later life suggests that mild to moderate alcohol consumption ... research has been conducted on subjects already rather elderly ... published in the December issue of the Journal ...
... MONDAY, Jan. 10 (HealthDay News) -- The H1N1 swine flu ... a vaccine that can protect people against multiple strains of ... were infected with the H1N1 virus and recovered had a ... variety of flu strains. The virus matched typical influenza ...
... MONDAY, Jan. 10 (HealthDay News) -- Patients given cholesterol-lowering drugs ... the brain may be at an increased risk of having ... well-known that statins help reduce the risk of heart disease ... in the brain. However, whether statins also benefit patients who ...
... quintessentially masculine, women in their fertile phase are more ... paired with George Clooney types. But women with ... their partners, a recent study co-authored by a University ... man,s intelligence has no effect on the extent to ...
... found that a protein that plays an important role in ... additional mechanisms that cause it to promote atherosclerosis, or clogging ... issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology ... antioxidant therapies have not yielded more positive results. ...
Cached Medicine News:Health News:Aggressive care raises Medicare costs in end-stage dementia 2Health News:Aggressive care raises Medicare costs in end-stage dementia 3Health News:Abstinence, heavy drinking, binge drinking associated with increased risk of cognitive impairment 2Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:Statins May Be Harmful After Stroke 2Health News:Statins May Be Harmful After Stroke 3Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2
Stainless Steel. Sterile. 2 pieces/box...
... attributes of the IMMULITE 2000, the IMMULITE ... Logic Driven Incubation (LDI). Using a newly ... be formatted for optimal performance with the ... assays, such as Siemens Diagnostics' cardiac biomarkers ...
... The SMS is a robotic sample feeder that ... systems via a robotic arm and the SMS ... 200 tubes and compatibility with clinical chemistry system ... make the SMS a practical and affordable solution ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
Medicine Products: